These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 251249)

  • 21. Stability study of azlocillin sodium in glass bottles and PVC bags containing intravenous admixtures.
    Puiggròs Boldú S; Pujol Cubells M; Girona Brumós V; Prat Aixelà J; Muñoz Juncosa M
    Boll Chim Farm; 1995 Sep; 134(8):467-71. PubMed ID: 7576447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenytoin sodium solubility in three intravenous solutions.
    Pfeifle CE; Adler DS; Gannaway WL
    Am J Hosp Pharm; 1981 Mar; 38(3):358-62. PubMed ID: 7223749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-use study of potential bacterial contamination of ophthalmic moxifloxacin.
    Mason BL; Alfonso EC; Miller D
    J Cataract Refract Surg; 2005 Sep; 31(9):1773-6. PubMed ID: 16246782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compatibility of diazepam with intravenous fluid containers and administration sets.
    Parker WA; MacCara ME
    Am J Hosp Pharm; 1980 Apr; 37(4):496-500. PubMed ID: 7377212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiologic quality assurance for intravenous admixtures in a small hospital.
    Doss HL; James JD; Killough DM; Snodgrass GL
    Am J Hosp Pharm; 1982 May; 39(5):832-5. PubMed ID: 6805321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterility of total parenteral nutrient solutions stored at room temperature for seven days.
    Takagi J; Khalidi N; Wolk RA; Tjolsen E; de Leon R; Wesley JR
    Am J Hosp Pharm; 1989 May; 46(5):973-7. PubMed ID: 2499191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrogen contamination of total parenteral nutrition solutions: a case report.
    Stansfield SA; Jones EL
    Can J Hosp Pharm; 1983; 36(1):21, 28. PubMed ID: 10310172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis as a tool to compare two methods of preparing and administering intravenous heparin solutions.
    Oszko MA; Fant WK
    Hosp Pharm; 1985 Aug; 20(8):576-8, 581-2. PubMed ID: 10311207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amnioinfusion: does the choice of solution adversely affect neonatal electrolyte balance?
    Puder KS; Sorokin Y; Bottoms SF; Hallak M; Cotton DB
    Obstet Gynecol; 1994 Dec; 84(6):956-9. PubMed ID: 7970476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining a time frame for sterility testing of intravenous admixtures.
    DeChant RL; Furtado D; Smith FM; Godwin HN; Domann DE
    Am J Hosp Pharm; 1982 Aug; 39(8):1305-8. PubMed ID: 6751079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Studies on bacteriologic contamination of potassium chloride solution 25% in multidose containers regularly used on hospital wards].
    Schramm G; Bianchi S
    Schweiz Med Wochenschr; 1982 Aug; 112(31-32):1099-100. PubMed ID: 6753141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro cyanide release from sodium nitroprusside in various intravenous solutions.
    Ikeda S; Frank PA; Schweiss JF; Homan SM
    Anesth Analg; 1988 Apr; 67(4):360-2. PubMed ID: 3354871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective.
    Maki DG; Botticelli JT; LeRoy ML; Thielke TS
    JAMA; 1987 Oct; 258(13):1777-81. PubMed ID: 3114506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous solution compatibility and filter-retention characteristics of trace-element preparations.
    Boddapati S; Yang K; Murty R
    Am J Hosp Pharm; 1981 Nov; 38(11):1731-6. PubMed ID: 6795924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Particulate contamination of amino acid solutions for parenteral use].
    Ferrari F; Bonferoni MC; Zamella C; La Manna A; Verrengio B; Pedroni M; Omodei-Sale A
    Boll Chim Farm; 1991 Nov; 130(10):402-8. PubMed ID: 1805875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of azacitidine in infusion fluids.
    Cheung YW; Vishnuvajjala BR; Morris NL; Flora KP
    Am J Hosp Pharm; 1984 Jun; 41(6):1156-9. PubMed ID: 6204528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous nitroglycerin delivery: dynamics and cost considerations.
    Nix DE; Tharpe WN; Francisco GE
    Hosp Pharm; 1985 Apr; 20(4):230-2. PubMed ID: 10311085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality-control plan for intravenous admixture programs. I: Visual inspection of solutions and environmental testing.
    Morris BG; Avis KE
    Am J Hosp Pharm; 1980 Feb; 37(2):189-95. PubMed ID: 7361790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution.
    Venkataramanan R; Burckart GJ; Ptachcinski RJ; Blaha R; Logue LW; Bahnson A; Giam CS; Brady JE
    Am J Hosp Pharm; 1986 Nov; 43(11):2800-2. PubMed ID: 3799618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compounding times and contamination rates associated with the preparation of intravenous admixtures in three types of plastic containers.
    Allinson RR; Stach PE; Sherrin TP; Latiolais CJ
    Am J Hosp Pharm; 1979 Apr; 36(4):513-7. PubMed ID: 433938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.